IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced a reverse stock split of its issued and outstanding common stock, par ...

Management provides Nasdaq Hearing Panel with a comprehensive executable plan for long term compliance LAWRENCEVILLE, N.J., July 15, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a ...

LAWRENCEVILLE, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that, in ...

Furthermore, IMUNON’s Phase 2 OVATION 2 Study of IMNN-001 for ovarian cancer showed significant improvements in survival rates, indicating promise for future treatment options.

IMUNON’s announcement is based on a press release statement from the clinical-stage biotechnology company. For deeper insights into IMUNON’s financial health and growth prospects, InvestingPro ...

Wall Street Zen upgraded shares of Imunon (NASDAQ:IMNN – Free Report) to a sell rating in a research note released on Friday morning. IMNN has been the topic of several other reports. D Boral ...

--IMUNON, Inc., a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced positive data from the Company’ s Phase 2 OVATION 2 Study showing that ...

IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

IMUNON previously reported positive safety and encouraging Phase 1 results with IMNN-001 administered as monotherapy or as combination therapy in patients with advanced peritoneally metastasized ...

Imunon, Inc. - GlobeNewswire - Thu May 15, 7:05AM CDT Company’s PlaCCine ® technology platform demonstrates better durability and other advantages compared to mRNA vaccines Results further ...

Management provides Nasdaq Hearing Panel with a comprehensive executable plan for long term compliance LAWRENCEVILLE, N.J., July 15, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-st ...

IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable ...